Selective apoptosis of breast cancer cells by siRNA targeting of BORIS

Biochemical and Biophysical Research Communications

Volumn 370, Issue 1, 2008, Pages 109-112

  Dougherty, Christopher J ^a   Ichim, Thomas E ^b,e   Liu, Liping ^b   Reznik, Gary ^f   Min, Wei Ping ^c   Ghochikyan, Anahit ^a,d   Agadjanyan, Michael G ^a,d   Reznik, Boris N ^b,e  

^a FLORIDA ATLANTIC UNIVERSITY   (United States)

^b OncoMune LLC   (United States)

^c UNIVERSITY OF WESTERN ONTARIO   (Canada)

^d INSTITUTE FOR MOLECULAR MEDICINE   (United States)

^e bioRASI LLC   (United States)

^f Vita Medical Center   (United States)

Author keywords

Apoptosis; BORIS; Breast cancer; Caspase; CTCF; siRNA; Zinc finger

Indexed keywords

PROTEIN CTCF; SMALL INTERFERING RNA; TRANSCRIPTION FACTOR; TRANSCRIPTION FACTOR BORIS; TUMOR SUPPRESSOR PROTEIN; UNCLASSIFIED DRUG; ZINC FINGER PROTEIN;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; BREAST CANCER; BREAST EPITHELIUM; CANCER REGRESSION; CELL SELECTION; CELL VIABILITY; CONTROLLED STUDY; DRUG POTENCY; DRUG TARGETING; EPIGENETICS; HUMAN; HUMAN CELL; HUMAN TISSUE; MOLECULAR MODEL; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; RNA INTERFERENCE; TRANSCRIPTION REGULATION; VACCINATION;

APOPTOSIS; BASE SEQUENCE; BREAST NEOPLASMS; CASPASE 3; CASPASE 7; CELL LINE, TUMOR; CELL SURVIVAL; DNA-BINDING PROTEINS; FEMALE; HUMANS; MOLECULAR SEQUENCE DATA; RNA, SMALL INTERFERING; TRANSFECTION;

MUS;

EID: 41849116616     PISSN: 0006291X     EISSN: 10902104     Source Type: Journal    
DOI: 10.1016/j.bbrc.2008.03.040     Document Type: Article

References (18)

1. Loukinov D.I., Pugacheva E., Vatolin S., Pack S.D., Moon H., Chernukhin I., Mannan P., Larsson E., Kanduri C., Vostrov A.A., Cui H., Niemitz E.L., Rasko J.E., Docquier F.M., Kistler M., Breen J.J., Zhuang Z., Quitschke W.W., Renkawitz R., Klenova E.M., Feinberg A.P., Ohlsson R., Morse III H.C., and Lobanenkov V.V. BORIS, a novel male germ-line-specific protein associated with epigenetic reprogramming events, shares the same 11-zinc-finger domain with CTCF, the insulator protein involved in reading imprinting marks in the soma. Proc. Natl. Acad. Sci. USA 99 (2002) 6806-6811
2. Klenova E.M., Morse III H.C., Ohlsson R., and Lobanenkov V.V. The novel BORIS + CTCF gene family is uniquely involved in the epigenetics of normal biology and cancer. Semin. Cancer Biol. 12 (2002) 399-414
3. Vatolin S., Abdullaev Z., Pack S.D., Flanagan P.T., Custer M., Loukinov D.I., Pugacheva E., Hong J.A., Morse III H., Schrump D.S., Risinger J.I., Barrett J.C., and Lobanenkov V.V. Conditional expression of the CTCF-paralogous transcriptional factor BORIS in normal cells results in demethylation and derepression of MAGE-A1 and reactivation of other cancer-testis genes. Cancer Res. 65 (2005) 7751-7762
4. Hong J.A., Kang Y., Abdullaev Z., Flanagan P.T., Pack S.D., Fischette M.R., Adnani M.T., Loukinov D.I., Vatolin S., Risinger J.I., Custer M., Chen G.A., Zhao M., Nguyen D.M., Barrett J.C., Lobanenkov V.V., and Schrump D.S. Reciprocal binding of CTCF and BORIS to the NY-ESO-1 promoter coincides with derepression of this cancer-testis gene in lung cancer cells. Cancer Res. 65 (2005) 7763-7774
5. Risinger J.I., Chandramouli G.V., Maxwell G.L., Custer M., Pack S., Loukinov D., Aprelikova O., Litzi T., Schrump D.S., Murphy S.K., Berchuck A., Lobanenkov V., and Barrett J.C. Global expression analysis of cancer/testis genes in uterine cancers reveals a high incidence of BORIS expression. Clin. Cancer Res. 13 (2007) 1713-1719
6. Lobanenkov V.V., Nicolas R.H., Adler V.V., Paterson H., Klenova E.M., Polotskaja A.V., and Goodwin G.H. A novel sequence-specific DNA binding protein which interacts with three regularly spaced direct repeats of the CCCTC-motif in the 5′-flanking sequence of the chicken c-myc gene. Oncogene 5 (1990) 1743-1753
7. Qi C.F., Martensson A., Mattioli M., Dalla-Favera R., Lobanenkov V.V., and Morse III H.C. CTCF functions as a critical regulator of cell-cycle arrest and death after ligation of the B cell receptor on immature B cells. Proc. Natl. Acad. Sci. USA 100 (2003) 633-638
8. Renaud S., Loukinov D., Bosman F.T., Lobanenkov V., and Benhattar J. CTCF binds the proximal exonic region of hTERT and inhibits its transcription. Nucleic Acids Res. 33 (2005) 6850-6860
9. Filippova G.N., Lindblom A., Meincke L.J., Klenova E.M., Neiman P.E., Collins S.J., Doggett N.A., and Lobanenkov V.V. A widely expressed transcription factor with multiple DNA sequence specificity, CTCF, is localized at chromosome segment 16q22.1 within one of the smallest regions of overlap for common deletions in breast and prostate cancers. Genes Chromosomes Cancer 22 (1998) 26-36
10. Ghochikyan A., Mkrtichyan M., Loukinov D., Mamikonyan G., Pack S.D., Movsesyan N., Ichim T.E., Cribbs D.H., Lobanenkov V.V., and Agadjanyan M.G. Elicitation of T cell responses to histologically unrelated tumors by immunization with the novel cancer-testis antigen, brother of the regulator of imprinted sites. J. Immunol. 178 (2007) 566-573
11. Mkrtichyan M., Ghochikyan A., Loukinov D., Davtyan H., Ichim T.E., Cribbs D.H., Lobanenkov V.V., and Agadjanyan M.G. DNA, but not protein vaccine based on mutated BORIS antigen significantly inhibits tumor growth and prolongs the survival of mice. Gene Ther. 15 (2008) 61-64
12. Mkrtichyan M., Ghochikyan A., Loukinov D., Davtyan H., Ichim T.E., Cribbs D.H., Lobanenkov V.V., and Agadjanyan M.G. DNA, but not protein vaccine based on mutated BORIS antigen significantly inhibits tumor growth and prolongs the survival of mice. Gene Ther. (2007)
13. Loukinov D., Ghochikyan A., Mkrtichyan M., Ichim T.E., Lobanenkov V.V., Cribbs D.H., and Agadjanyan M.G. Antitumor efficacy of DNA vaccination to the epigenetically acting tumor promoting transcription factor BORIS and CD80 molecular adjuvant. J. Cell. Biochem. 98 (2006) 1037-1043
14. D'Arcy V., Pore N., Docquier F., Abdullaev Z.K., Chernukhin I., Kita G.X., Rai S., Smart M., Farrar D., Pack S., Lobanenkov V., and Klenova E. BORIS, a paralogue of the transcription factor, CTCF, is aberrantly expressed in breast tumours. Br. J. Cancer (2008)
15. Kunigal S., Lakka S.S., Gondi C.S., Estes N., and Rao J.S. RNAi-mediated downregulation of urokinase plasminogen activator receptor and matrix metalloprotease-9 in human breast cancer cells results in decreased tumor invasion, angiogenesis and growth. Int. J. Cancer 121 (2007) 2307-2316
16. Ohri S.S., Vashishta A., Proctor M., Fusek M., and Vetvicka V. Depletion of procathepsin D gene expression by RNA interference: a potential therapeutic target for breast cancer. Cancer Biol. Ther. 6 (2007)
17. + chronic myeloid leukemia cells by a lentiviral vector-delivered anti-bcr/abl small hairpin RNA. Oligonucleotides 13 (2003) 401-409
18. Bokoch G.M. Caspase-mediated activation of PAK2 during apoptosis: proteolytic kinase activation as a general mechanism of apoptotic signal transduction. Cell Death Differ. 5 (1998) 637-645